citadel

Read more here.

Citadel upgraded its rating on Hyatt Hotels (NYSE: H) from Neutral to Add. At the same time, Citadel raised its price target on the company's stock from $47 to $48. In today's trading, Hyatt added 2.12% to its value to trade around $40.85.

Citadel reiterated its Reduce rating and PT of $29 on Texas Instruments (NYSE: TXN). In a research report published today, Citadel states, "Given its sell-in revenue recognition model and expectations for an increase in already elevated internal inventories... TI's earnings could be among the most...

Citadel is out with its report today on Carnival (NYSE: CCL), and Royal Caribbean Cruises (NYSE: RCL), raising its PT's to $49 and $57 respectively. In a note to clients, Citadel writes, "We continue to value both CCL and RCL on a P/E basis, at multiples of 15.5x and 14.5x 2012E EPS, respectively...

Citadel is out with its report today on Intel (NASDAQ: INTC). maintaining Add. In a note to clients, Citadel writes, "While the fate of the Intel's discrete application processors is unlikely to matter much to the stock in the near term, we think the opposite is true of Intel's total handset...

Citadel is out with its report today on Leap Wireless (NASDAQ: LEAP) and MetroPCS (NYSE: PCS), initiating coverage on LEAP and PCS. In a note to clients, Citadel writes, "The U.S. wireless industry in the midst of a shift in favor of prepaid (nocontract) versus postpaid (contract) tiers. We...

Citadel is out with its report today on Marvell Technologies (NASDAQ: MRVL), maintaining Neutral. In a note to clients, Citadel writes, "Year to date, Marvell has been among the worst performing names in our universe, down 23% vs. a 5% increase for the rest of our coverage. At issue have been...

Citadel is out with its report today on Savient Pharmaceuticals (NASDAQ: SVNT), downgrading SVNT to Neutral. In a note to clients, Citadel writes, "With the slow ramp for Krystexxa in the U.S., and with a lack of meaningful catalysts until late 2011 / early 2012, we are downgrading SVNT shares to...

Citadel Securities has downgraded Savient Pharmaceuticals (NASDAQ: SVNT) from Buy to Neutral and has established a $9 price target.

Fox Business Network (FBN) Senior Correspondent Charlie Gasparino reports that Citadel got a “wide ranging subpoena” from the Federal Government and FOX Business Network has learned “two other hedge funds received subpoenas” as well. Excerpts from the report are below, courtesy of Fox Business...